SSKN - Strata Skin Sciences Inc Stock Price, Fair Value and News

0.40USD+0.02 (+5.26%)Market Closed

Market Summary

USD0.40+0.02

Market Closed

5.26%

SSKN Stock Price

View Fullscreen

SSKN RSI Chart

SSKN Valuation

Market Cap

14.0M

Price/Earnings (Trailing)

-1.23

Price/Sales (Trailing)

0.43

EV/EBITDA

-6.87

Price/Free Cashflow

-3.15

SSKN Price/Sales (Trailing)

SSKN Profitability

Operating Margin

52.71%

EBT Margin

-33.56%

Return on Equity

-120.47%

Return on Assets

-28.37%

Free Cashflow Yield

-31.79%

SSKN Fundamentals

SSKN Revenue

Revenue (TTM)

32.5M

Rev. Growth (Yr)

-10.74%

Rev. Growth (Qtr)

-22.27%

SSKN Earnings

Earnings (TTM)

-11.4M

Earnings Growth (Yr)

-18.8%

Earnings Growth (Qtr)

11.23%

Breaking Down SSKN Revenue

Last 7 days

5.3%

Last 30 days

-23.1%

Last 90 days

-21.6%

Trailing 12 Months

-57.9%

How does SSKN drawdown profile look like?

SSKN Financial Health

Current Ratio

1.05

Debt/Equity

1.6

Debt/Cashflow

-0.01

SSKN Investor Care

Shares Dilution (1Y)

0.51%

Diluted EPS (TTM)

-0.33

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	32.5M	0	0	0
2023	36.7M	35.8M	35.3M	33.4M
2022	31.2M	32.9M	34.6M	36.2M
2021	22.2M	25.5M	27.6M	30.0M
2020	30.8M	27.1M	25.3M	23.1M
2019	30.6M	30.9M	30.7M	31.6M
2018	31.2M	30.2M	30.4M	29.9M
2017	30.4M	31.1M	30.8M	31.8M
2016	26.0M	33.2M	32.6M	30.7M
2015	898.2K	1.3M	9.4M	18.5M
2014	489.5K	570.1K	680.4K	914.8K
2013	410.9K	479.5K	518.1K	536.0K
2012	0	0	0	278.0K
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Strata Skin Sciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 01, 2023	gov shmuel	bought	8,955	0.447781	20,000	coo
Nov 16, 2023	rubinstein samuel	sold	-320	0.32	-1,000	-
Aug 16, 2023	22nw, lp	bought	1,023,070	0.5521	1,853,060	-
Aug 10, 2023	lesovitz christopher	bought	10,152	0.6701	15,151	chief financial officer
Aug 10, 2023	moccia robert joseph	bought	28,308	0.674	42,000	chief executive officer
Jul 05, 2023	walker patricia s	acquired	37,500	1.03	36,408	-
Jul 05, 2023	strang douglas	acquired	35,000	1.03	33,981	-
Jul 05, 2023	rubinstein samuel	acquired	35,000	1.03	33,981	-
Jul 05, 2023	shamir nachum	acquired	40,000	1.03	38,835	-
Jul 05, 2023	humphries william d.	acquired	37,500	1.03	36,408	-

Which funds bought or sold SSKN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	VIMA LLC	added	100	78.00	106	-%
May 15, 2024	STATE STREET CORP	unchanged	-	-1,971	4,328	-%
May 15, 2024	MORGAN STANLEY	unchanged	-	-88.00	193	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-7.00	-	-%
May 15, 2024	22NW, LP	unchanged	-	-924,169	2,029,840	1.75%
May 15, 2024	Tower Research Capital LLC (TRC)	added	10.65	-1,423	4,516	-%
May 15, 2024	Nantahala Capital Management, LLC	reduced	-50.61	-2,273,620	1,167,950	0.07%
May 15, 2024	PERRITT CAPITAL MANAGEMENT INC	unchanged	-	-17,210	37,800	0.02%
May 15, 2024	GREENWOOD GEARHART INC	sold off	-100	-3.00	-	-%
May 15, 2024	CANNELL CAPITAL LLC	sold off	-100	-151,721	-	-%

Are Funds Buying or Selling SSKN?

Are funds buying SSKN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SSKN

No. of Funds

Unveiling Strata Skin Sciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	nantahala capital management, llc	8.9%	3,128,132	SC 13G/A
Aug 18, 2023	22nw fund, lp	15.4%	5,369,954	SC 13G/A
Feb 14, 2023	nantahala capital management, llc	12.7%	4,393,685	SC 13G/A
Feb 13, 2023	22nw fund, lp	9.9%	3,439,261	SC 13G/A
Feb 14, 2022	nantahala capital management, llc	13.3%	4,575,812	SC 13G/A
Jan 14, 2022	22nw fund, lp	5.8%	2,002,059	SC 13G
Feb 16, 2021	kent lake capital llc	4.9%	1,658,043	SC 13G/A
Feb 12, 2021	nantahala capital management, llc	13.9%	4,683,908	SC 13G/A
Jun 23, 2020	broadfin capital, llc	4.54%	0	SC 13D/A
Jun 10, 2020	nantahala capital management, llc	13.9%	4,685,062	SC 13G/A

Recent SEC filings of Strata Skin Sciences Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	8-K	Current Report
May 15, 2024	10-Q	Quarterly Report
Apr 29, 2024	10-K/A	Annual Report
Apr 26, 2024	8-K	Current Report
Mar 28, 2024	10-K	Annual Report
Mar 27, 2024	8-K	Current Report
Feb 26, 2024	8-K	Current Report
Feb 21, 2024	8-K	Current Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Strata Skin Sciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.83%	-87.10%	-0.09	0.28	5.77%	8.23%

Strata Skin Sciences Inc News

Latest updates

Strata Skin Sciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-22.3%	6,754	8,689	8,852	8,250	7,567	10,602	9,413	9,105	7,041	9,057	7,711	7,382	5,827	6,717	5,613	4,030	6,730	8,898	7,480	7,725	7,483
Cost Of Revenue	-5.5%	3,674	3,888	3,898	3,932	3,179	3,754	3,614	4,112	2,913	3,057	2,335	2,621	2,114	2,176	2,383	2,066	2,331	2,772	2,855	2,815	2,874
Gross Profit	-35.8%	3,080	4,801	4,954	4,318	4,388	6,848	5,799	4,993	4,128	6,000	5,376	4,761	3,713	4,541	3,230	1,964	4,399	6,126	4,625	4,910	4,609
Costs and Expenses	-27.6%	5,969	8,242	5,569	6,280	6,974	6,714	6,585	6,687	6,431	6,622	5,841	5,684	6,105	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	6,622	5,841	5,684	6,105	4,893	4,391	3,579	5,347	6,183	5,354	5,893	5,850
S&GA Expenses	9.3%	3,018	2,760	3,038	3,416	3,742	3,785	3,754	4,146	3,616	3,719	3,295	3,160	2,932	2,592	2,051	1,442	2,953	3,092	2,887	2,958	3,066
R&D Expenses	-36.6%	241	380	248	374	315	441	216	209	163	276	371	403	384	324	411	247	292	214	249	235	304
EBITDA Margin	0.2%	-0.10*	-0.10*	0.05*	0.04*	0.03*	0.03*	-0.02*	-0.01*	0.07*	0.05*	0.02*	0.00*	-0.11*	-	-	-	-	-	-	-	-
Interest Expenses	-0.8%	524	528	528	298	286	275	244	208	199	205	53.00	26.00	30.00	249	-21.00	-18.00	1.00	-82.00	-153	-145	-135
Income Taxes	-	-	-	-	-	-	63.00	-	-	-	22.00	4.00	4.00	4.00	68.00	72.00	47.00	88.00	-38.00	-22.00	-46.00	-43.00
Earnings Before Taxes	-	-	-	-	-	-	-97.00	-995	-1,892	-2,502	-827	-517	1,086	-2,414	-375	-1,182	-1,633	-947	-553	-882	-1,128	-1,376
EBT Margin	-2.5%	-0.34*	-0.33*	-0.16*	-0.15*	-0.15*	-0.15*	-0.18*	-0.17*	-0.09*	-0.09*	-0.08*	-0.11*	-0.25*	-	-	-	-	-	-	-	-
Net Income	11.2%	-3,368	-3,794	-1,053	-3,148	-2,835	-160	-995	-1,892	-2,502	-849	-521	1,082	-2,418	-443	-1,254	-1,680	-1,035	-515	-860	-1,082	-1,333
Net Income Margin	-7.5%	-0.35*	-0.32*	-0.20*	-0.20*	-0.16*	-0.15*	-0.18*	-0.18*	-0.09*	-0.09*	-0.08*	-0.12*	-0.26*	-	-	-	-	-	-	-	-
Free Cashflow	-340.6%	-1,529	-347	-1,826	-756	-2,609	-1,520	-1,221	-887	-1,032	-461	-605	-492	-587	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-4.7%	40.00	42.00	47.00	55.00	49.00	52.00	53.00	54.00	55.00	47.00	47.00	45.00	46.00	47.00	47.00	46.00	46.00	47.00	48.00	48.00	48.00
Current Assets	-14.8%	13.00	16.00	20.00	21.00	15.00	15.00	19.00	19.00	19.00	20.00	20.00	23.00	24.00	25.00	25.00	24.00	23.00	24.00	24.00	24.00	24.00
Cash Equivalents	-3.1%	7.00	7.00	7.00	9.00	3.00	5.00	7.00	10.00	11.00	13.00	13.00	10.00	10.00	18.00	11.00	11.00	8.00	16.00	16.00	16.00	16.00
Inventory	0.8%	3.00	3.00	6.00	6.00	6.00	3.00	6.00	5.00	5.00	3.00	3.00	3.00	3.00	3.00	4.00	3.00	3.00	3.00	4.00	4.00	3.00
Net PPE	-0.4%	12.00	12.00	8.00	8.00	8.00	10.00	7.00	7.00	7.00	7.00	6.00	6.00	6.00	6.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
Goodwill	0%	7.00	7.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00
Liabilities	4.4%	31.00	29.00	31.00	38.00	30.00	30.00	31.00	31.00	31.00	21.00	21.00	19.00	22.00	21.00	21.00	19.00	18.00	19.00	19.00	19.00	18.00
Current Liabilities	3.4%	13.00	12.00	12.00	14.00	13.00	13.00	14.00	14.00	14.00	13.00	12.00	18.00	20.00	19.00	19.00	17.00	17.00	17.00	12.00	11.00	10.00
Long Term Debt	0.2%	15.00	15.00	15.00	15.00	8.00	7.00	7.00	7.00	7.00	7.00	7.00	0.00	1.00	1.00	1.00	2.00	-	-	5.00	6.00	6.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	0.00	2.00	1.00	1.00	1.00	-	-	3.00	2.00	1.00
LT Debt, Non Current	-100.0%	-	15.00	15.00	15.00	8.00	7.00	7.00	7.00	7.00	7.00	7.00	0.00	1.00	1.00	1.00	2.00	-	-	5.00	6.00	6.00
Shareholder's Equity	-25.7%	9.00	13.00	16.00	17.00	19.00	22.00	22.00	22.00	24.00	25.00	26.00	26.00	24.00	26.00	26.00	27.00	28.00	29.00	29.00	29.00	30.00
Retained Earnings	-1.4%	-241	-238	-234	-233	-230	-227	-227	-226	-224	-221	-220	-220	-221	-218	-218	-217	-215	-214	-214	-213	-212
Additional Paid-In Capital	0.0%	251	251	250	250	249	249	249	248	248	247	247	246	245	245	244	244	244	243	243	243	242
Shares Outstanding	0%	35.00	35.00	35.00	35.00	35.00	35.00	35.00	35.00	35.00	34.00	34.00	34.00	34.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	17.00	-	-	-	17.00	-	-	-	26.00	-	-	-	24.00	-	-	-	49.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-153.4%	-804	1,506	-997	175	-1,203	179	-694	-56.00	-353	669	452	234	153	346	549	603	598	1,113	710	70.00	336
Share Based Compensation	-61.2%	112	289	337	352	325	191	455	452	368	80.00	320	581	662	357	403	410	430	312	257	303	323
Cashflow From Investing	60.9%	-725	-1,853	-829	-931	-1,406	-1,699	-527	-831	-1,310	-1,130	-4,530	-726	-740	-712	-717	-134	-596	-1,416	-423	-518	-434
Cashflow From Financing	-Infinity%	-18.00	-	-104	6,965	-	-500	-	-	-	-	92.00	-	-	18.00	-	-	-	-296	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SSKN Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Condensed Consolidated Statements of Operations [Abstract]
Revenues, net	$ 6,754	$ 7,567
Cost of revenues	3,674	3,179
Gross profit	3,080	4,388
Operating expenses:
Engineering and product development	241	315
Selling and marketing	3,018	3,742
General and administrative	2,710	2,917
Total operating expenses	5,969	6,974
Loss from operations	(2,889)	(2,586)
Other (expense) income:
Interest expense	(524)	(286)
Interest income	45	37
Other (expense), income net	(479)	(249)
Net loss	$ (3,368)	$ (2,835)
Net loss per share of common stock - basic (in dollars per share)	$ (0.1)	$ (0.08)
Net loss per share of common stock - diluted (in dollars per share)	$ (0.1)	$ (0.08)
Weighted average shares of common stock outstanding - basic (in shares)	35,060,920	34,862,092
Weighted average shares of common stock outstanding - diluted (in shares)	35,060,920	34,862,092

SSKN Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 5,237	$ 6,784
Restricted cash	1,334	1,334
Accounts receivable, net of allowance for credit losses of $306 and $222 at March 31, 2024 and December 31, 2023, respectively	3,630	4,440
Inventories	2,695	2,673
Prepaid expenses and other current assets	343	312
Total current assets	13,239	15,543
Property and equipment, net	11,726	11,778
Operating lease right-of-use assets	1,508	626
Intangible assets, net	6,825	7,319
Goodwill	6,519	6,519
Other assets	231	231
Total assets	40,048	42,016
Current liabilities:
Accounts payable	3,592	3,343
Accrued expenses and other current liabilities	6,269	6,306
Deferred revenues	2,366	2,120
Current portion of operating lease liabilities	300	352
Current portion of contingent consideration	61	53
Total current liabilities	12,588	12,174
Long-term debt, net	15,075	15,044
Deferred revenues and other liabilities	480	552
Deferred tax liability	186	186
Operating lease liabilities, net of current portion	1,166	237
Contingent consideration, net of current portion	1,121	1,135
Total liabilities	30,616	29,328
Commitments and contingencies (Note 13)
Stockholders' equity:
Series C convertible preferred stock, $0.10 par value; 10,000,000 shares authorized, no shares issued and outstanding	0	0
Common stock, $0.001 par value; 150,000,000 shares authorized; 35,060,920 shares issued and outstanding at March 31, 2024 and December 31, 2023	35	35
Additional paid-in capital	250,823	250,711
Accumulated deficit	(241,426)	(238,058)
Total stockholders' equity	9,432	12,688
Total liabilities and stockholders' equity	$ 40,048	$ 42,016

About Strata Skin Sciences Inc

STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. The company products include XTRAC and Pharos excimer lasers, and VTRAC lamp systems for the treatment systems that are used for the treatment of psoriasis, vitiligo, and other skin conditions. It also provides TheraClear Acne Therapy System for the treatment of mild to moderate inflammatory, comedonal, and pustular acne. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.

CEO	Mr. Robert J. Moccia
WEBSITE	strataskinsciences.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	114

Strata Skin Sciences Inc Frequently Asked Questions

What is the ticker symbol for Strata Skin Sciences Inc? What does SSKN stand for in stocks?

SSKN is the stock ticker symbol of Strata Skin Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Strata Skin Sciences Inc (SSKN)?

As of Fri May 17 2024, market cap of Strata Skin Sciences Inc is 14.02 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SSKN stock?

You can check SSKN's fair value in chart for subscribers.

What is the fair value of SSKN stock?

You can check SSKN's fair value in chart for subscribers. The fair value of Strata Skin Sciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Strata Skin Sciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SSKN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Strata Skin Sciences Inc a good stock to buy?

The fair value guage provides a quick view whether SSKN is over valued or under valued. Whether Strata Skin Sciences Inc is cheap or expensive depends on the assumptions which impact Strata Skin Sciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SSKN.

What is Strata Skin Sciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, SSKN's PE ratio (Price to Earnings) is -1.23 and Price to Sales (PS) ratio is 0.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SSKN PE ratio will change depending on the future growth rate expectations of investors.